IS5875A - Established phenyl derivatives, their production and use - Google Patents

Established phenyl derivatives, their production and use

Info

Publication number
IS5875A
IS5875A IS5875A IS5875A IS5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A
Authority
IS
Iceland
Prior art keywords
established
production
phenyl derivatives
phenyl
derivatives
Prior art date
Application number
IS5875A
Other languages
Icelandic (is)
Other versions
IS2215B (en
Inventor
H. Dahl Bjarne
Christophersen Palle
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of IS5875A publication Critical patent/IS5875A/en
Publication of IS2215B publication Critical patent/IS2215B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IS5875A 1998-10-22 2001-03-02 Establishes phenyl derivatives, their production and use IS2215B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801362 1998-10-22
PCT/DK1999/000575 WO2000024707A1 (en) 1998-10-22 1999-10-19 Substituted phenyl derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
IS5875A true IS5875A (en) 2001-03-02
IS2215B IS2215B (en) 2007-03-15

Family

ID=8104026

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5875A IS2215B (en) 1998-10-22 2001-03-02 Establishes phenyl derivatives, their production and use

Country Status (27)

Country Link
US (1) US6706749B2 (en)
EP (2) EP1514867A3 (en)
JP (2) JP3960754B2 (en)
KR (1) KR100799892B1 (en)
CN (1) CN1263733C (en)
AP (1) AP2001002103A0 (en)
AT (1) ATE286021T1 (en)
AU (1) AU759275B2 (en)
BR (1) BR9914638A (en)
CA (1) CA2342626A1 (en)
DE (1) DE69922986T2 (en)
EE (1) EE04849B1 (en)
ES (1) ES2235522T3 (en)
HU (1) HUP0103673A3 (en)
IL (2) IL141479A0 (en)
IS (1) IS2215B (en)
NO (1) NO20011956L (en)
NZ (1) NZ510098A (en)
OA (1) OA11665A (en)
PL (1) PL198852B1 (en)
PT (1) PT1123274E (en)
RU (1) RU2218328C2 (en)
SK (1) SK5222001A3 (en)
TR (1) TR200101126T2 (en)
UA (1) UA73284C2 (en)
WO (1) WO2000024707A1 (en)
ZA (1) ZA200101824B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002224758A1 (en) * 2001-01-23 2002-08-06 Nordic Bioscience A/S Method for screening compounds for activity in treating an osteoclast related bone disease
DE10102977A1 (en) 2001-01-23 2002-08-01 Thomas Jentsch Test system for the development of therapeutic agents, in particular active ingredients for the treatment of osteoporosis
WO2003000245A1 (en) * 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
WO2003014727A1 (en) * 2001-08-08 2003-02-20 Chugai Seiyaku Kabushiki Kaisha Remedies for heart diseases
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
ATE372770T1 (en) * 2002-08-01 2007-09-15 Neurosearch As COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES THAT RESPOND TO ANTI-ANGIOGENIC THERAPY
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
CN100497302C (en) * 2002-09-05 2009-06-10 神经研究公司 Diarylurea derivatives and their use as chloride channel blockers
PT1565429E (en) 2002-11-21 2009-07-23 Neurosearch As Diaryl ureido derivatives and their medical use
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
ATE411301T1 (en) 2003-06-17 2008-10-15 Neurosearch As DIPHENYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
DE602004000260T2 (en) * 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego DIARYL AND ARYLHETEROARYL DRUG DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR SUITABLE FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES THEREOF
JP2007504202A (en) 2003-09-04 2007-03-01 ポセイドン ファーマシュティカルズ アクティーゼルスカブ ERG channel opener for treating cardiac arrhythmias
WO2005023238A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
ATE548353T1 (en) * 2004-03-23 2012-03-15 Arena Pharm Inc METHOD FOR PRODUCING SUBSTITUTED N-ARYL-N'-Ä3-(1H-PYRAZOLE-5-YL)PHENYLÜ-UREAS AND INTERMEDIATE THEREOF.
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
RU2420520C2 (en) * 2004-04-02 2011-06-10 Прана Биотехнолоджи Лимитэд Neurologically active compositions
ATE453617T1 (en) * 2004-05-12 2010-01-15 Proteotech Inc SUBSTITUTED N-ARYLBENZAMIDE AND RELATED COMPOUNDS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES
SA05260357B1 (en) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto
US20080015223A1 (en) * 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
EP1858877B1 (en) 2005-01-14 2014-03-12 Gilead Connecticut, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
US20080200530A1 (en) * 2005-01-19 2008-08-21 Unett David J Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1996190A1 (en) 2006-03-14 2008-12-03 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers or bkca channel modulators
CN101534826A (en) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 Methods of treating age-related macular degeneration (AMD)
JP5406018B2 (en) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof
CA2646076C (en) * 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
SG171681A1 (en) 2006-05-18 2011-06-29 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5393677B2 (en) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド Imidazo [1,2-a] pyridine derivatives as modulators of 5-HT2A serotonin receptors for the treatment of disorders associated with 5-HT2A serotonin receptors
WO2009068509A1 (en) * 2007-11-26 2009-06-04 Neurosearch A/S Novel benzamide derivatives useful as potassium channel modulators
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2741731A1 (en) * 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
WO2011022028A2 (en) * 2009-05-18 2011-02-24 Tufts University Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2011053468A1 (en) * 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
RU2434851C1 (en) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Cyclic n,n'-diarylthioureas or n,n'-diarylureas - antagonists of androgen receptors, anti-cancer medication, method of obtaining and application
US9834537B2 (en) 2013-11-27 2017-12-05 Korea Institute Of Science And Technology Compounds as chloride channel blocking agent
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (en) 2015-07-15 2018-09-04 Axovant Sciences Gmbh method for the prophylaxis and / or treatment of visual hallucinations in a subject in need
EP3458052B1 (en) 2016-05-17 2019-11-06 Scandion Oncology A/S Combination treatment of cancer
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US20230348450A1 (en) * 2020-09-14 2023-11-02 Genzyme Corporation Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
EP4355324A1 (en) 2021-06-14 2024-04-24 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
AU2022293969A1 (en) 2021-06-14 2023-12-14 Scandion Oncology A/S Methods of increasing the plasma drug exposure of anticancer agents
TW202321205A (en) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Thermodynamically stable form of sco-101
CN117229258B (en) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-tetrazolyl aryl urea derivatives and preparation method and application thereof
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts
WO2025125679A1 (en) 2023-12-15 2025-06-19 Scandion Oncology A/S Improved anti-cancer treatment regimen
CN119039190B (en) * 2024-09-20 2026-03-10 上海信诺维生物医药有限公司 WRN inhibitor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055786A (en) * 1963-07-12 1967-01-18 Ici Ltd Urea derivatives
FR2100943A1 (en) * 1970-07-23 1972-03-24 Ici Ltd O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents
DE2928485A1 (en) * 1979-07-14 1981-01-29 Bayer Ag USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS
CA1156250A (en) * 1979-10-15 1983-11-01 Eastman Kodak Company Cyan dye-forming couplers
DE3100575A1 (en) * 1981-01-10 1982-09-02 Dr. Karl Thomae Gmbh, 7950 Biberach "NEW BENZOESAEURS, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS"
DE3682136D1 (en) 1985-07-31 1991-11-28 Hoechst Ag N-SUBSTITUTED 5-NITROANTHRANILE ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS.
US4889612A (en) 1987-05-22 1989-12-26 Abbott Laboratories Ion-selective electrode having a non-metal sensing element
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
JPH05504968A (en) 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム Glycinamide derivatives, their production and pharmaceuticals containing them
US5489612A (en) 1991-08-23 1996-02-06 The University Of Alabama At Birmingham Research Foundation Calixarene chloride-channel blockers
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
DK41193D0 (en) * 1993-04-07 1993-04-07 Neurosearch As ion channel openers
CA2137755C (en) * 1994-06-07 2002-07-02 William H. Waugh Palliation of sickle cell disorders by phenylurea, benzylurea, or phenylethylurea or by a homolog ring-substituted with one methoxyl, methyl, or hydroxyl radical
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
DE4447096C2 (en) * 1994-12-29 1998-12-03 Rehau Ag & Co Stabilized chlorine-containing polymers and use of functional urea derivatives as stabilizers
JPH11503110A (en) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
HUP0004421A3 (en) * 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
CA2255858C (en) * 1996-05-24 2007-09-11 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
US6297261B1 (en) * 1997-04-22 2001-10-02 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO1999032463A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

Also Published As

Publication number Publication date
PL198852B1 (en) 2008-07-31
CA2342626A1 (en) 2000-05-04
CN1322194A (en) 2001-11-14
RU2218328C2 (en) 2003-12-10
JP2002528432A (en) 2002-09-03
JP2003246773A (en) 2003-09-02
NO20011956D0 (en) 2001-04-20
PL347371A1 (en) 2002-04-08
EP1123274B1 (en) 2004-12-29
EP1123274A1 (en) 2001-08-16
ES2235522T3 (en) 2005-07-01
US20020032210A1 (en) 2002-03-14
ATE286021T1 (en) 2005-01-15
TR200101126T2 (en) 2001-09-21
EE200100185A (en) 2002-08-15
IL141479A (en) 2006-08-20
BR9914638A (en) 2001-07-03
SK5222001A3 (en) 2002-05-09
AU759275B2 (en) 2003-04-10
HUP0103673A3 (en) 2003-03-28
KR100799892B1 (en) 2008-01-31
IL141479A0 (en) 2002-03-10
KR20010080270A (en) 2001-08-22
HK1040699A1 (en) 2002-06-21
DE69922986D1 (en) 2005-02-03
HUP0103673A2 (en) 2002-02-28
AP2001002103A0 (en) 2001-03-31
WO2000024707A1 (en) 2000-05-04
ZA200101824B (en) 2002-03-05
CN1263733C (en) 2006-07-12
EE04849B1 (en) 2007-06-15
IS2215B (en) 2007-03-15
EP1514867A3 (en) 2005-03-23
US6706749B2 (en) 2004-03-16
DE69922986T2 (en) 2005-07-07
AU6325999A (en) 2000-05-15
OA11665A (en) 2004-12-08
PT1123274E (en) 2005-04-29
NZ510098A (en) 2003-09-26
JP3960754B2 (en) 2007-08-15
UA73284C2 (en) 2005-07-15
NO20011956L (en) 2001-04-20
EP1514867A2 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
IS5875A (en) Established phenyl derivatives, their production and use
NO20021449D0 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
IS6385A (en) New uses and new N-azabicyclo-amide derivatives
NO20012567D0 (en) Azepinoindole derivatives, preparation and use thereof
IS2040B (en) Pyrazoline derivatives, their production and use as pharmaceuticals
DK1454907T3 (en) Quninazoline and pyridopyrmidine derivatives
ATE435861T1 (en) 12,13-CYCLOPROPANE-EPOTHILONE DERIVATIVES
NO20021379D0 (en) Benzodiazepine derivatives, preparation and use thereof
DE69924799D1 (en) girdle
DK1073672T3 (en) Antipicornaviral compounds, their preparation and use
IS2174B (en) Establishes phenyl-piperazine derivatives, their production and use
NO20013237L (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
DK1202996T3 (en) Titanium compounds, manufacture and use thereof
IS7829A (en) New 1,4-diazabicycloalkane derivatives, their production and use
NO20003825D0 (en) 1,3,4 - oxadiazolone derivatives
DK1025100T3 (en) 3-substituted tetrahydropyridopyrimidinone derivatives, their preparation and their use
IS5731A (en) 4, 5, 6 and 7-indole and indoline derivatives, their production and use
IS2247B (en) Benzofuran derivatives, their production and use
NO20006479D0 (en) Tienopyridine compounds, their preparation and use
IS6403A (en) New heteroaryl derivatives, their production and use
NO996156L (en) Substituted cycloheptans, their preparation and use
DK1043306T3 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
NO20020404D0 (en) Streptogramin derivatives, their production and compounds thereof
IS7131A (en) New 2,4-diaminothiazole derivatives
DK1123274T3 (en) Substituted phenyl derivatives, their preparation and use